Athira Pharma Inc. (ATHA)
0.26
-0.02 (-7.47%)
At close: Apr 03, 2025, 3:59 PM
0.27
3.71%
After-hours: Apr 03, 2025, 05:00 PM EDT
-7.47% (1D)
| Bid | 0.26 |
| Market Cap | 10.25M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.52 |
| PE Ratio (ttm) | -0.1 |
| Forward PE | -0.32 |
| Analyst | Hold |
| Ask | 0.29 |
| Volume | 72,368 |
| Avg. Volume (20D) | 204,083 |
| Open | 0.26 |
| Previous Close | 0.28 |
| Day's Range | 0.25 - 0.28 |
| 52-Week Range | 0.25 - 3.67 |
| Beta | 3.01 |
About ATHA
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkins...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2020
Employees 26
Stock Exchange NASDAQ
Ticker Symbol ATHA
Website https://www.athira.com
Analyst Forecast
According to 4 analyst ratings, the average rating for ATHA stock is "Hold." The 12-month stock price forecast is $11.25, which is an increase of 4185.71% from the latest price.
Stock Forecasts4 months ago
-12.01%
Althira Pharma shares are trading lower after the ...
Unlock content with
Pro Subscription
5 months ago
+15.73%
Athira Pharma shares are trading higher after the company announced it will present results from its Phase 2/3 LIFT-AD clinical trial of Fosgonimeton to treat Alzheimer's disease.
